SCHEMBL9397304

SCHEMBL9397304

CC(CC(C#N)(c1ccccc1)c1ccccn1)N(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.44
OPRM1 P35372 3/20 0.44
DRD4 P21917 2/20 0.44
DRD3 P35462 2/20 0.44
DRD2 P14416 1/20 0.44
CYP3A4 P08684 3/20 0.41
CHRM2 P08172 2/20 0.41
CYP2C19 P33261 1/20 0.41
OPRK1 P41145 2/20 0.41
KCNH2 Q12809 2/20 0.41
BLM P54132 2/20 0.41
SLC22A2 O15244 1/20 0.41
SLC22A1 O15245 1/20 0.41
PGR P06401 1/20 0.41
THRB P10828 1/20 0.41
ADRB3 P13945 1/20 0.41
PMP22 Q01453 1/20 0.41
PDE3A Q14432 1/20 0.41
SLC47A1 Q96FL8 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8061907 0.84 OPRM1 (0.56) CYP2D6OPRM1DRD4DRD3DRD2
SCHEMBL8059835 0.84 OPRM1 (0.56) CYP2D6OPRM1DRD4DRD3DRD2
SCHEMBL504205 0.84 OPRM1 (0.56) CYP2D6OPRM1DRD4DRD3DRD2
SCHEMBL9450076 0.79 CYP2D6 (0.45) CYP2D6OPRM1DRD4DRD3DRD2
SCHEMBL11619910 0.78 CYP2D6 (0.70) CYP2D6OPRM1DRD4DRD3DRD2
SCHEMBL9581143 0.78 CYP3A4 (0.60) CYP2D6OPRM1DRD4DRD3DRD2
SCHEMBL10838731 0.76 CYP3A4 (0.59) CYP2D6CYP3A4CHRM2CYP2C19OPRK1
SCHEMBL11471791 0.76 CCR1 (0.46) CYP2D6OPRM1DRD4DRD3DRD2
SCHEMBL11600408 0.75 CYP3A4 (0.55) CYP2D6OPRM1DRD4DRD3DRD2
Hydrochloric Acid SCHEMBL11114957 0.75 CYP3A4 (0.58) CYP2D6CYP3A4CHRM2CYP2C19OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0452809-B1 A therapeutic agent for pollakiuria, urinary urgency or incontinence of urine comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives FUJISAWA PHARMACEUTICAL CO (JP) 1994-07-27 EP disclosed
US-5202331-A THERAPEUTIC AGENT FOR DYSURIA COMPRISING ALPHA-PHENYL-ALPHA-PYRIDYLALKANOIC ACID DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-04-13 US disclosed
EP-0452809-A2 A therapeutic agent for pollakiuria, urinary urgency or incontinence of urine comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-10-23 EP disclosed
EP-0105458-B1 ALPHA-ARYL-ALPHA-PYRIDYLALKANOIC ACID DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-11-23 EP disclosed
US-4564621-A ANTIULCER AND ANTISPASMODIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-01-14 US disclosed